HIV 1/2 4th Gen, RFLX Conf

Sample type: Serum

Other names: HIV 1/2 AB/ag Rflx conf, HIV 1/2 ag/AB combo, Human immunodeficiency virus

Non-Reactive
A non-reactive result on an HIV 1/2 4th Generation test indicates that no HIV antigens or antibodies were detected in the blood sample at the time of testing. This typically suggests that the individual has not been infected with HIV. However, it's important to consider the window period – the time between potential exposure to HIV and the point at which the test can reliably detect the virus. If the test is conducted during this window period, it might not yet detect a recent infection. In such cases, especially if there's potential recent exposure to HIV, a repeat test after the end of the window period (usually a few weeks to a few months) is recommended for conclusive results. Additionally, a non-reactive result does not indicate immunity to HIV and should not diminish the importance of preventive measures against HIV transmission.
Reactive
A reactive result on an HIV 1/2 4th Generation test indicates a preliminary positive for HIV, meaning that the test has detected either HIV antigens (specific proteins from the virus, such as the p24 antigen) or antibodies (produced by the body in response to the virus) in the blood sample. This suggests that the individual has been exposed to HIV. However, a reactive result is not a definitive diagnosis of HIV infection. It requires further confirmatory testing, typically involving a more specific assay like an HIV-1/HIV-2 antibody differentiation immunoassay or a nucleic acid test (NAT), to conclusively determine the presence and type of HIV infection. This step is crucial due to the possibility of false positives in initial screenings, especially in low prevalence settings. WILL REFLEX TO HIV-1/HIV-2 CONFIRMATION WHEN RESULT IS REACTIVE.

Human Immunodeficiency Virus (HIV) is categorized into two distinct types: HIV-1 and HIV-2. Both are retroviruses that attack the body's immune system, but they have differences in their geographical prevalence, transmission rates, and progression to Acquired Immunodeficiency Syndrome (AIDS).

HIV-1: This is the most common type of HIV and is found worldwide. It's responsible for the vast majority of HIV infections globally. HIV-1 is characterized by its rapid transmission and progression. It is more aggressive and infects cells faster than HIV-2, leading to a quicker decline in immune function if left untreated. HIV-1 is divided into four groups: M (Main), O (Outlier), N (Non-M, Non-O), and P, with Group M responsible for the majority of infections worldwide. Further, Group M is divided into multiple subtypes and circulating recombinant forms (CRFs).

HIV-2: This type is less common and is predominantly found in West Africa, with some cases in India and Europe. Compared to HIV-1, HIV-2 is transmitted less efficiently, particularly from mother to child and through heterosexual contact. The progression of HIV-2 to AIDS is generally slower, and it may have a longer asymptomatic stage. HIV-2 is also less responsive to certain antiretroviral therapies, requiring specific treatment regimens.

In terms of diagnosis, the 4th generation HIV tests are capable of detecting both HIV-1 and HIV-2. These tests look for both antibodies (the body’s immune response to the virus) and antigens (specific parts of the virus; in the case of HIV, the p24 antigen is commonly targeted). The ability to detect antigens allows these tests to identify HIV infections earlier than antibody-only tests.

The management of HIV involves antiretroviral therapy (ART), which is effective for both types, although the specific treatment regimen may vary depending on whether it's HIV-1 or HIV-2. ART works by reducing the viral load in the body to undetectable levels, improving the quality of life and life expectancy of infected individuals, and significantly reducing the risk of transmission.

Understanding the differences between HIV-1 and HIV-2 is crucial for effective treatment and epidemiological control. Both types of HIV can lead to the weakening of the immune system, making individuals more susceptible to other infections and diseases. Early detection and appropriate treatment are key to managing the infection and preventing its spread.

The management of HIV involves antiretroviral therapy (ART), which is effective for both types, although the specific treatment regimen may vary depending on whether it's HIV-1 or HIV-2. ART works by reducing the viral load in the body to undetectable levels, improving the quality of life and life expectancy of infected individuals, and significantly reducing the risk of transmission.

Understanding the differences between HIV-1 and HIV-2 is crucial for effective treatment and epidemiological control. Both types of HIV can lead to the weakening of the immune system, making individuals more susceptible to other infections and diseases. Early detection and appropriate treatment are key to managing the infection and preventing its spread.

The marker "HIV 1/2 4th Gen, RFLX Conf" on a sexually transmitted disease (STD) test panel refers to the fourth-generation testing for Human Immunodeficiency Virus (HIV) Types 1 and 2, with reflex to confirmatory testing. This advanced testing methodology significantly enhances the early detection of HIV, the virus responsible for Acquired Immunodeficiency Syndrome (AIDS). Fourth-generation tests are designed to detect both HIV antigens (specifically, the p24 antigen which appears soon after infection and before antibodies are made) and antibodies (the immune response to the virus). This dual detection approach allows for the identification of acute HIV infections earlier than previous generation tests that only detected antibodies.

The "RFLX Conf" part of the marker indicates that if the initial test is reactive, indicating the possible presence of HIV, the sample will automatically undergo additional confirmatory testing. This typically involves an HIV-1/HIV-2 antibody differentiation immunoassay to confirm the presence of HIV and determine whether it is type 1 or type 2. In some cases, if the differentiation assay is inconclusive, a nucleic acid test (NAT) may be performed to detect the virus's genetic material directly.

The inclusion of this test in STD panels is critical due to the asymptomatic nature of early HIV infection and the significant public health implications of undiagnosed HIV. Early detection through the fourth-generation test allows for timely initiation of antiretroviral therapy (ART), which is crucial for managing HIV, reducing the risk of transmission, and improving long-term health outcomes. Additionally, early intervention has been shown to significantly reduce the risk of HIV-related complications and transmission to others, underscoring the importance of including this test in comprehensive STD testing and early intervention strategies.

NOTE: The performance of this assay has not been established for individuals younger than 2 years of age. Nearly all infants born to HIV-infected mothers passively acquire maternal antibody and may test antibody positive until 18 months regardless of infection status. Definitive diagnosis requires other assays, including HIV nucleic acid tests.

HIV 1/2 4th Gen, RFLX Conf
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond HIV 1/2 4th Gen, RFLX Conf — 10,000+ markers explained
One HIV 1/2 4th Gen, RFLX Conf result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Article Review Log
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro